To characterize the nature of the immunoreactive transferrin receptor in human serum, antisera were developed to peptide sequences of the extracellular domain of human transferrin receptor between amino acids 107 and 120 and the intracellular domain between amino acids 40 and 54. Antisera against the extracellular domain exhibited reactivity against both purified intact receptor and immunopurified circulating receptor, whereas antisera against the intracellular domain reacted only with intact receptor. Using competitive binding enzyme-linked immunosorbent assays, transferrin receptor in ultracentrifuged sera from normal subjects and patients with sickle cell anemia could be detected with antisera against the extracellular but not the UBLICATIONS from several laboratories indicate that P transfemn receptor can be detected invariably in human sera using sensitive immunologic methods.I4 Recent studies from our laboratory have shown that the serum transferrin receptor is a truncated soluble form resulting from a cleavage in the extracellular domain between arginine, at amino acid position 100, and leucine, at amino acid position 101.5 On the other hand, in vitro studies with maturing sheep reticulocytes have indicated that transferrin receptor is released intact in small vesicles termed exosomes in which the extracellular domain of the transfemn receptor is positioned on the external surface?-" It has been suggested in several reports that this particular form accounts for the immunoreactivity detected in human s e r~m . * *~, '~, '~ In our recent study demonstrating that serum receptor consists predominantly of a truncated soluble form, the material used for amino acid sequencing was isolated by affinity purification, and it is conceivable that a particulate form of circulating receptor would not be extracted by this purification approach. Moreover, the monoclonal enzyme-linked immunosorbent assay (ELISA) used in our laboratory for routine measurements of serum transfemn receptor does not distinguish between the intact and soluble forms of transfemn receptor. The current investigation was undertaken to further characterize the nature of the serum transfemn receptor in humans by extending our search for a vesicular or intact form of transfemn receptor in serum. To distinguish and quantify the intact and soluble forms of the circulating receptor, we developed polyclonal antibodies to peptide sequences in the extracellular and intracellular domains for use in competitive binding ELISAs. Medicine and Biochemistry, Kansas University Medical Center, Kansas City, KS. Submitted June 26, 1992; accepted September 8, 1992 0006-497I/93/8101-0032$3.00/0 intracellular domain. When the pellet obtained by ultracentrifugation of these sera was assayed after solubilization in 1 % teric (polyoxyethylene-9-lauryl ether), only 0.6% of total serum receptor was detected in normal subjects and 3.8% in subjects with sickle cell disease. Roughly equal amounts of this pelleted immunoactivity were detected with antibodies against the extracellular and intracellular domains.
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1 % teric (polyoxyethylene-9-lauryl ether), only 0.6% of total serum receptor was detected in normal subjects and 3.8% in subjects with sickle cell disease. Roughly equal amounts of this pelleted immunoactivity were detected with antibodies against the extracellular and intracellular domains.
These results indicate that less than 1 % of transferrin receptor in normal human sera is intact receptor consistent with an exosomal origin and that virtually all circulating transferrin receptor is in the form of a truncated extracellular domain.
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MATERIALS AND METHODS
Keyhole limpet hemocyanin (KLH), glutaraldehyde, complete and incomplete Freund's adjuvant, ammonium sulfate, glycine, tris-[hydroxymethyl]aminomethane (TRIS), polyoxyethylene-9-lauryl ether (teric), and bovine serum albumin (BSA) were purchased from Sigma Chemical Co (St Louis, MO). +Phenylenediamine dihydrochloride was from Eastman Kodak (Rochester, NY). Peroxidaseconjugated swine Ig to rabbit Ig was obtained from Dako (Carpinteria, CA). Affi-gel protein A gel, 4% to 20% polyacrylamide gradient gel and nitrocellulose membrane were from Bio-Rad Laboratories (Richmond, CA). Intact transfemn receptor was purified from human placenta using a transfemn affinity column by the method of Turkewitz et Immunoaffinity chromatography using monoclonal antitransfemn receptor antibody was employed to purify soluble receptor from human serum. 5 The two peptide sequences selected from the deduced amino acid sequence15 for the preparation of antisera were positioned on either side of the truncation site of the soluble transfenin receptor. The specific sequences were chosen to maximize regional hydrophilicity while maintaining an optimal position of lysine residues for complexing the KLH carrier protein. The peptide in the extracellular domain was located six residues distal to the truncation site of the intact receptor between amino acid residues 107 and 120 (Fig 1) . The chosen sequence PVREEPGEDFPAAR possessed high hydrophilicity but required a lysine residue to be appended at the C-terminus to facilitate coupling to the carrier protein KLH. The intracellular peptide sequence LAVDEEENADNNTKA was located in the cytoplasmic domain of the molecule between amino acid residues 40 and 54 and possessed one lysine residue at the second position from the C-terminus.
The two peptides were synthesized commercially by the solid-phase methodf6 at Multiple Peptide Systems (San Diego, CA). Purification of the desired peptide from the unpurified mixture of peptide sequences was accomplished by high-performance liquid chromatography (HPLC) using a Varian Liquid Chromatograph, model Vista 5500 (Varian Instruments, Sunnyvale, CA) and a Vydac CIS reverse phase column (4.6 mm X 25 cm) (Alltech Associates Inc, Deerfield, IL). The sample was eluted with a flow rate of 1 mL/min using a linear gradient of 5% to 65% acetonitrile/O. I% trifluoroacetic acid for 30 minutes. Peptide conjugation to the camer protein KLH was performed as described previously."
Polyclonal antisera against the purified peptides were prepared by injecting female New Zealand white rabbits subcutaneously with 0.5 mg of peptide conjugate emulsified in 500 pL complete Freund's adjuvant and 500 pL normal saline. The an-
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Predicted amino acid sequence ofthe amino-terminal end of the transferrin receptor." The transmembrane sequence (amino acids 62 to 89) is underlined. The selected domain-specific sequences are doubly underlined and consist of residues 40 to 54 in the cytoplasmic domain and 107 to 120 in the extracellulardomain. The arrow between residues 100 (arginine) and 101 (leucine) indicates the site of soluble receptor truncation. Cysteine residues at position 89 and 98 are involved in disulfide linkage to form the receptor dimer.
imals were immunized a further two times at 2-week intervals by the same technique and bled IO days after the final injection.
A portion of the antisera to synthetic peptides was precipitated with ammonium sulfate and purified using protein A chromatography as follows. Ammonium sulfate was slowly added to the antisera at 40% saturation and allowed to stand for 2 hours at 4OC. The supernatant, obtained by centrifugation at 3.800~ for 20 minutes was brought to 50% saturation with ammonium sulfate, allowed to stand for 2 hours, and recentrifuged. Both pellets were pooled and loaded onto an affi-gel protein A gel column and washed with phosphatebuffered saline (PBS) until the AZm approached zero. Antibody was then eluted with 0. I mol/L glycine, pH 2.5, immediately neutralized with I mol/L TRIS, pH 8.3, and dialyzed against PBS.
Purified intact and serum receptor were analyzed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) under nonreducing conditions by the method of Laemmlils and transblotted to nitrocellulose membrane as described previou~ly.'~ After blocking with I% nonfat dry milk in PBS for I hour, the nitrocellulose membrane strips were incubated for 2 hours with IO mL cytoplasmic or extracellular domain peptide antibody that had been purified using protein A chromatogr;phy or Electrophoresis and Western blotting. for 2 hours. The immunoreactive proteins were detected by adding the chromogenic substrate 4-chloro-I -naphthol after extensive washing with PBS.
Competitive binding ELISA. The protocol for the competitive binding ELSA was modified from that described by TortTvit et aLm Flat-bottomed 96-well microtiter plates (NUNC-lntermed: NUNC Inc, Naperville, IL) were coated overnight at 4OC with 200 ng/mL purified intact receptor diluted in 0.05 mol/L carbonate buffer, pH 9.6, blocked for 30 minutes with 0.5% BSA in carbonate buffer, and washed three times with PBS and 0.05% Tween (PBST). In the competition mixture, 80 pL of standard or sample in PBST was added to each well followed by 20 pL of diluted peptide antisera and incubated for 2 hours at room temperature. After washing three times with PBST, swine antirabbit IgG conjugated with HRP diluted 1: 1,OOO with I% BSA/PBST (100 pL) was added to each well and incubated at room temperature for 2 hours. After thorough washing, 100 pL of +phenylenediamine dihydrochloride (1.9 mmol/L) in 0.15 mol/L citrate-phosphate buffer, pH 5.0, containing 0.01% hydrogen peroxide, was added and after a 30-minute incubation in the dark, the reaction was stopped by adding 25 pL of 25% sulfuric acid. A4992 was determined on a microplate reader (Titertek Multiskan, Flow Laboratories, McLean, VA). The standard curve was obtained by plotting the concentration of affinity-purified transferrin receptor added in the assay against the difference in A4992 from measurements performed with PBST only.
Preparation ofhitman sera. Plasma samples were obtained from three normal subjects and five patients with sickle cell anemia. Samples were diluted I:I with saline and ultracentrifuged at l OO. OOOg for 90 minutes at 4°C. The resulting supernatants were stored, and the pellets were solubilized in Hank's buffered salt solution containing 1 mmol/L TRIS (HBSSTRIS) and I% teric, pH 7.4. while rotating continuously overnight at 4OC. The solubilized materials were recentrifuged at 15,OOO.q for 15 minutes and supernatants collected. The serum transfenin receptor concentration was measured in the native serum before and after ultracentrifugation and in the solubilized pellets. Both the competitive binding ELISA using polyclonal peptide antibodies outlined previously and an ELSA employing monoclonal antibodies to the intact receptor as described previousl? were used. 
RESULTS
The i"un0RactivitY and specificity of the peptide antibodies for both Purified intact and serum transfemn recep tors was first examined by Western blotting (Fig 2) . MoAb against the intact receptor detected placental receptor at M, = 190,000 and serum receptor at 85,000 under nonreducing electrophoretic conditions. An identical reactivity pattem was obtained with the antibody raised against the extracellular peptide domain. However, the peptide antibody against the intracellular domain recognized only the intact receptor.
These reactivities were confirmed when competitive binding ELISAs were established using peptide antibodies against the extracellular and intracellular domain. When increasing amounts of intact placental receptor were added, a parallel dose response was obtained with the intracellular and extracellular domain antibody (Fig 3) . On the other hand, when increasing amounts of affinity-purified serum receptor were added, only the antisera against the extracellular domain gave a dose-response curve (Fig 4) .
To assess the ability of these assays to provide a quantitative measure of intact and soluble receptor when contained in the same mixture, simultaneous measurements were performed with assays using the two domain-specific antisera (Table I) . Samples containing only intact receptor could be assayed using either the extracellular or intracellular assay system, whereas the latter assay was unable to detect the soluble form of transfenin receptor. Thus, in samples containing a mixture of the intact and soluble form of transfemn receptor, subtraction of the assay value obtained with the intracellular peptide antibody from the extracellular assay provided a reliable measure of the concentration of the truncated soluble form.
These competitive binding ELISAs were next used to determine the quantities of soluble and intact transfemn receptor in human sera. Because of greater sensitivity and qualitatively identical reactivity, the monoclonal ELISA was used rather than the competitive ELISA established with peptide antibodies against the extracellular domain. In postultracentrifugation supematant of both normal sera and sera from patients with sickle cell anemia, negligible amounts of transfemn receptor were detected with the assay against the intracellular domain that measures only intact receptor ( 2), whereas predictable amounts were measured with the monoclonal ELISA. In normal serum, both ELISAs also failed to detect significant quantities of transfemn receptor in the solubilized postcentrifugation pellet. On the other hand, detectable quantities of transfemn receptor could be measured in this serum fraction in patients with sickle cell anemia using the monoclonal ELISA. The amount varied between 1.7% and 6.7% of the total quantity present in the serum with a mean of 3.8%. In the sera from patients with sickle cell anemia, the two assay systems detected comparable amounts of receptor in the solubilized pellet. In four of the five sera examined, greater amounts of transfemn receptor were detected with the assay developed for the cytoplasmic portion of the receptor, suggesting that there was a small amount of intracellular remnant of the transfemn receptor in addition to intact receptor in the pelleted material.
DISCUSSION
Prior work suggesting that the exosome is the major pathway of transferrin receptor loss from cells has been conducted primarily in animals. In rat studies performed by Beguin et al,12 the electrophoretic pattern of the immunoreactive plasma transferrin receptor from normal and iron-deficient rats was considered to be the same as intact placental receptor. Using gel filtration, this group later concluded that transferrin receptor in human serum was also in the same molecular form as intact placental receptor:
In a more recent study, the release of transferrin receptor during the maturation of rat reticulocytes in vitro was studied.13 These workers reported that two thirds of the receptor shed during a 44-hour incubation was present in vesicles and the remainder in a soluble form. The latter was found to be similar in size to the vesicular and cellular receptor, leading these investigators to conclude that the soluble form of the transferrin receptor is released as an intact molecule from the vesicles. These observations are in sharp contrast to recent studies with K562 erythroleukemic cells that released both an intact exosomal form and a quantitatively dominant truncated monomeric form2' identical to that recently described in human sera.5
In the present study, antisera were developed against peptide sequences in the extracellular and intracellular domains of human transferrin receptor to further characterize the nature of circulating receptor in human sera. These antisera exhibited the expected reactivities with intact placental and truncated serum receptor when examined by Western blotting (Fig 2) . The establishment of quantitative assays with these immunologic reagents proved to be the major obstacle in this investigation. We were unsuccessful in our efforts to establish a sandwichtype ELISA using varying combinations of polyclonal antibodies and MoAbs against intact receptor or synthetic peptides. The results were not improved by purifying antibodies with protein A or peptide affinity chromatography. All combinations failed to give a dose-response curve with purified intact receptor. Because free peptide bound to the microtiter plate could readily bind the peptide antibody, it must be assumed that these difficulties were caused by diminished affinity of the antisera for the linear peptide sequences when present as the native protein.
These problems were circumvented by the use of a competitive binding ELISA in which various fractions of human sera were incubated with an appropriate dilution of the peptide antisera. When assayed in microtiter plates coated with intact human receptor, a progressive decrease in the binding of the peptide antisera to this receptor occurred when increasing quantities of transferrin receptor were added. Because the sensitivity of the sandwich ELISA with MoAb was greater than the competitive binding ELISA using extracellular domain peptide antibodies, the former was used in conjunction with the intracellular domain peptide antibody competitive binding ELISA when examining the nature of circulating transfemn receptor. It should be noted that the use of these two assays in tandem permits the quantitative detection of mixtures of either intact and soluble receptor or intact and the cytoplasmic remnant, but it does not provide measurements of mixtures of all three forms of the receptor.
In normal subjects, negligible amounts of transfemn receptor were detected in the solubilized pellet following ultracentrifugation; the fraction in which vesicular or exosomal receptor would be contained. The pelletable receptor accounted for only 0.6% of the total serum receptor (range 0.5% to 0.7%) and was thus virtually undetectable. When the concentration of circulating receptor was substantially increased as in patients with sickle cell anemia, the soluble truncated form in the ultracentrifuged supernatant of serum again was the predominant form of the circulating receptor, although more receptor was detectable in the pelleted fraction. The latter accounted for an average of 3.8% of the total serum receptor with a range of 1.7% to 6.7% based on measurements using the monoclonal ELISA. The monoclonal assay performed in conjunction with the competitive ELISA using the intracellular domain antibody indicated a slightly higher concentration of transfemn receptor containing the intracellular domain, except in the patient with the highest concentration of circulating receptor. These findings are consistent with an exosome containing intact receptor and a small amount of additional cytoplasmic remnant.
The present investigation provides additional evidence that the predominant form of the circulating transfemn receptor in human serum is a truncated monomeric form of transferrin receptor. The majority of investigations which have led to evidence that transfemn receptor is released from cells in intact vesicles have used maturing reticulocytes from animals with marked hemolysis. Therefore, it is not surprising that small amounts of receptor can be detected in this form in patients with severe hemolytic anemia. In addition to the patients with sickle cell anemia examined in the present study, we have detected receptor in pelleted form averaging 5.9% in patients with autoimmune hemolytic anemia and 3.9% in patients with thrombotic thrombocytopenic purpura. Nevertheless, the predominant, if not only, form in native serum 
